Martinez Steve R, Hoon Dave S B
Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, California 90404, USA.
J Cell Biochem. 2005 Oct 15;96(3):473-83. doi: 10.1002/jcb.20556.
The management of malignant cutaneous melanoma is problematic. Current clinical prognostic factors do not adequately predict disease recurrence and overall survival in a significant subset of patients. Adjuvant therapies for melanoma are notoriously toxic and associated with significant morbidity. Furthermore, it has been difficult to predict which patients will respond best to these treatments, if at all. DNA and RNA biomarkers have been developed to help overcome these problems. Biomarkers have been shown to upstage patients with melanoma, but are the assays sensitive and specific enough for clinical use as predictors of disease outcome or treatment response? We review our experience with DNA and RNA biomarkers in terms of their prognostic and predictive capabilities in malignant melanoma and outline their likely role in the future of melanoma staging, surveillance, and treatment.
恶性皮肤黑色素瘤的管理存在问题。目前的临床预后因素并不能充分预测相当一部分患者的疾病复发和总生存期。黑色素瘤的辅助治疗毒性很大，且伴有明显的发病率。此外，很难预测哪些患者对这些治疗（如果有的话）反应最佳。已经开发出DNA和RNA生物标志物来帮助克服这些问题。生物标志物已被证明可使黑色素瘤患者的分期升高，但这些检测对于作为疾病预后或治疗反应预测指标的临床应用而言，其敏感性和特异性是否足够呢？我们根据DNA和RNA生物标志物在恶性黑色素瘤中的预后和预测能力回顾我们的经验，并概述它们在黑色素瘤分期、监测和治疗未来可能发挥的作用。
